DeepMed Research

Shanghai Pharmaceuticals Holding Co.,Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Phase 2

Recruiting

Conditions: Breast Cancer Brain Metastases

Interventions: Drug: SPH4336 Tablets

First Posted Date: 2023-05-24

Last Posted Date: 2024-08-16

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 52

Registration Number: NCT05872347

Locations: 🇨🇳
Liuzhou people's Hospital, Liuzhou, Guangxi, China
🇨🇳
Anyang Cancer Hospital, Anyang, Henan, China
🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China

and more 22 locations

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Phase 2

Recruiting

Conditions: Locally Advanced or Metastatic Breast Cancer

Interventions: Drug: SPH4336 Tablets
Drug: SPH4336 Tablets Placebo

First Posted Date: 2023-05-16

Last Posted Date: 2025-04-11

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 254

Registration Number: NCT05860465

Locations: 🇨🇳
Liuzhou people's Hospital, Liuzhou, Guangxi, China
🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳
Anyang Cancer Hospital, Anyang, Henan, China

and more 19 locations

A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

Phase 2

Recruiting

Conditions: Mild to Moderate Ulcerative Colitis

Interventions: Drug: SPH3127 Tablets with Dose A
Drug: SPH3127 Tablets with Dose B
Drug: SPH3127 Tablets placebo

First Posted Date: 2023-03-15

Last Posted Date: 2025-04-11

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 108

Registration Number: NCT05770609

Locations: 🇨🇳
The First Affiliated Hospital of University of South China, Hengyang, Hunan, China
🇨🇳
Peking University Third Hospital, Beijing, China
🇨🇳
General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China

and more 22 locations

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Phase 2

Recruiting

Conditions: Locally Advanced or Metastatic Breast Cancer

Interventions: Drug: SPH4336 Tablets 400mg
Drug: SPH4336 Tablets Placebo

First Posted Date: 2023-02-27

Last Posted Date: 2025-01-28

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 374

Registration Number: NCT05744687

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳
Affiliated Cancer Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China

and more 6 locations

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Phase 2

Recruiting

Conditions: Acute Ischemic Stroke

Interventions: Drug: Placebo

First Posted Date: 2023-01-17

Last Posted Date: 2025-04-11

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 300

Registration Number: NCT05686642

Locations: 🇨🇳
Beijing Luhe Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
🇨🇳
Harrison International Peace Hospital, Hengshui, Hebei, China

and more 25 locations

Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Phase 2

Completed

Conditions: Diabetic Kidney Disease

Interventions: Drug: SPH3127 matching placebo+valsartan
Drug: SPH3127+SPH3127matching placebo+valsartan matching placebo
Drug: SPH3127+valsartan matching placebo

First Posted Date: 2022-10-25

Last Posted Date: 2025-02-19

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 305

Registration Number: NCT05593575

Locations: 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
The 900 Hospital of the Joint Service Support Force of the People's Liberation Army of China, Fuzhou, Fujian, China
🇨🇳
Zigong Fourth People's Hospital, Zigong, Sichuan, China

and more 42 locations

Study on Human Mass Balance of SPH3127 Tablets

Phase 1

Completed

Conditions: Primary Mild and Moderate Hypertension

Interventions: Drug: SPH3127

First Posted Date: 2022-10-25

Last Posted Date: 2022-12-07

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 6

Registration Number: NCT05593562

Locations: 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Drug-drug Interaction Study of SPH3127

Phase 1

Completed

Conditions: Drug Drug Interaction

Interventions: Drug: SPH3127 tablet
Drug: Itraconazole
Drug: Rifampin

First Posted Date: 2022-05-03

Last Posted Date: 2022-07-29

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 40

Registration Number: NCT05359055

Locations: 🇨🇳
West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China

Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: SPH3127 tablet
Drug: Valsartan

First Posted Date: 2022-05-03

Last Posted Date: 2024-05-07

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 957

Registration Number: NCT05359068

Locations: 🇨🇳
Beijing Pinggu Hospital, Beijing, Beijing, China
🇨🇳
Lanzhou University Second Hospital, Lanzhou, Gansu, China
🇨🇳
Liuzhou people's Hospital, Liuzhou, Guangxi, China

and more 37 locations

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Early Phase 1

Recruiting

Conditions: HER2-positive Advanced Solid Tumors

Interventions: Drug: SPH5030 tablets

First Posted Date: 2022-02-17

Last Posted Date: 2025-02-20

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 150

Registration Number: NCT05245058

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Anyang Cancer Hospital, Anyang, Henan, China
🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

and more 14 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy